News Sentiment

DWTX sentiment intelligence

Dogwood Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.42 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

74/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-4.7% over one week, -7.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Price to earnings forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 74/100 classification
One-week reaction -4.7% Price reacting lower
Trend fit Trend inactive -7.8% over four weeks
Fair value -82.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 32
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
GlobeNewswire 11
Market source 10
Stock Titan 6
TradingView 3
simplywall.st 3
MarketBeat 2
The Standard (HK) 2
marketscreener.com 1

Event Lens

What the news is about

Classified themes
Earnings 19
Market update 18
Deals and strategy 4
Guidance 3
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-46 of 46
GlobeNewswire Direct company coverage

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

Dogwood Therapeutics reported its third-quarter 2025 financial results, highlighting significant progress in its clinical trials and pipeline development. The company has enrolled 100 patients in its Halneuron® Phase 2b trial and secured an exclusive worldwide license for SP16, a

Tone
Positive 66/100
Event
Earnings
Published
06 Nov 2025 08:45
Source
GlobeNewswire
Stock Titan Direct company coverage

VIRI SEC Filings - Virios Therapeutics, Inc. 10-K, 10-Q, 8-K Forms

This page provides access to SEC filings for Virios Therapeutics (VIRI) and its successor, Dogwood Therapeutics (DWTX), after a business combination with Wex Pharmaceuticals in October 2024. It includes 10-K, 10-Q, 8-K, and Form 4 filings, featuring AI-powered summaries and real-

Tone
Negative 39/100
Event
Market update
Published
13 Aug 2025 03:10
Source
Stock Titan
GlobeNewswire Direct company coverage

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Dogwood Therapeutics announced the enrollment of the first 50 patients in its ongoing Halneuron® Phase 2b trial for Chemotherapy-Induced Neuropathic Pain (CINP). The company expects interim data readout for approximately 100 patients in Q4 2025 and plans to release full results i

Tone
Positive 75/100
Event
Earnings
Published
07 Aug 2025 13:08
Source
GlobeNewswire
Intellectia AI Direct company coverage

DWTX Stock: Price, Forecast, Financials & AI Analysis

Dogwood Therapeutics, Inc. (DWTX) is a biopharmaceutical company focused on developing therapies for pain and fatigue-related disorders, including a non-opioid analgesic program with Halneuron for cancer pain and an antiviral program. The company has seen significant clinical pro

Tone
Neutral 50/100
Event
Guidance
Published
27 Jan 2025 09:39
Source
Intellectia AI
Investing.com Direct company coverage

DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth

Virios Therapeutics Llc (DWTX) stock reached a 52-week high of $15.74, showing strong momentum with over 45% growth in the past week, despite being considered overvalued by InvestingPro's Fair Value analysis. The company is facing potential Nasdaq delisting due to low stockholder

Tone
Positive 67/100
Event
Market update
Published
23 Jan 2025 12:42
Source
Investing.com
GlobeNewswire Direct company coverage

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dogwood Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the listing compliance matter. This news comes as the company anticipates top-line results from its Phase 2a study of IMC-2 for Long-COVID in mid-November 2024 and

Tone
Positive 67/100
Event
Earnings
Published
30 Oct 2024 21:39
Source
GlobeNewswire
The Standard (HK) Direct company coverage

Investors wooed for new analgesic

CK Life Sciences is seeking new investors for the continued development of its analgesic drug, Halneuron, following a merger of its biotech subsidiary Wex Pharmaceuticals with US-listed Virios Therapeutics. The new entity, Dogwood Therapeutics, aims to secure incremental funding

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Oct 2024 11:10
Source
The Standard (HK)
The Standard (HK) Direct company coverage

CK Life unit to merge with Nasdaq biotech

CK Life Sciences International announced that its wholly-owned subsidiary will merge with Nasdaq-listed Virios Therapeutics. The combined entity, to be renamed Dogwood Therapeutics, will remain listed on Nasdaq. This strategic move involves CK Life selling Pharmagesic to Virios f

Tone
Positive 82/100
Event
Market update
Published
08 Oct 2024 11:41
Source
The Standard (HK)
Market source Direct company coverage

Virios Therapeutics Transforms into Dogwood Therapeutics

Virios Therapeutics has announced its merger with Pharmagesic, a subsidiary of Sealbond Limited, resulting in the formation of Dogwood Therapeutics, Inc. The newly branded company will focus on developing non-opioid pain treatments and antiviral drugs for long-term health conditi

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Oct 2024 03:51
Source
Market source
citybiz Direct company coverage

Virios Therapeutics And Wex Pharmaceuticals To Merge

Virios Therapeutics and Wex Pharmaceuticals have announced a definitive share exchange agreement to merge in an all-stock transaction, forming Dogwood Therapeutics, Inc. (NASDAQ: DWTX). The combined company will focus on developing three assets: Halneuron® for chemotherapy-induce

Tone
Positive 82/100
Event
Market update
Published
07 Oct 2024 22:09
Source
citybiz
Market source Direct company coverage

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Virios Therapeutics and Wex Pharmaceuticals have announced a business combination to form Dogwood Therapeutics, Inc. (NASDAQ: DWTX). This new company will focus on developing three assets: Halneuron® for chemotherapy-induced neuropathic pain, IMC-1 for fibromyalgia, and IMC-2 for

Tone
Neutral 50/100
Event
Market update
Published
07 Oct 2024 17:27
Source
Market source
GlobeNewswire Direct company coverage

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc.

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. are combining to form Dogwood Therapeutics, Inc. (Nasdaq: DWTX), focusing on developing treatments for chemotherapy-induced neuropathic pain, fibromyalgia, and Long-COVID. The new company secured $19.5 million in financing a

Tone
Positive 82/100
Event
Market update
Published
07 Oct 2024 07:05
Source
GlobeNewswire